Logo image of AGN

Allergan Plc (AGN) Stock News

NYSE:AGN - New York Stock Exchange, Inc. -

193.02  +0.03 (+0.02%)

After market: 193.7 +0.68 (+0.35%)

AGN Latest News, Press Relases and Analysis

News Image
20 days ago - MarketBeat

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?

Mentions: TEVA JNJ CVS WBA ...

News Image
a year ago - Seeking Alpha

AbbVie cites tailwinds to Botox sales from weight loss drugs

AbbVie's (ABBV) wrinkle therapy Botox-led aesthetics franchise may benefit from the increasing demand for obesity drugs in the long-term. Find out the reasons.

Mentions: ABBV

News Image
a year ago - Seeking Alpha

AbbVie sees maintaining Botox position in aesthetics: report (NYSE:ABBV)

Despite increasing competition, AbbVie reportedly expects Botox to maintain its leading market share position in the aesthetics market. Read more here.

Mentions: ABBV JPM RVNC EOLS

News Image
a year ago - Seeking Alpha

BioMarin could be very 'digestible' to larger cap peers in US/Europe - analyst

BioMarin's shares surge 12% after activist investor Elliott Management takes $1 billion stake; potential takeover target for larger cap peer.

Mentions: BAC BMRN

News Image
a year ago - Seeking Alpha

AbbVie Allergan reports positive Phase 3 data for new wrinkle treatment (NYSE:ABBV)

AbbVie (ABBV) Allergan Aesthetics reports positive Phase 3 results for its new wrinkle therapy, BoNT/E, for the treatment of glabellar lines between eyebrows. Read more here.

Mentions: ABBV

News Image
a year ago - Seeking Alpha

AbbVie says late-stage study supports Botox for platysma prominence

Allergan Aesthetics, a unit of AbbVie (ABBV), said that top-line results from a second phase 3 trial of Botox (onabotulinumtoxin A) for a muscle disruption that impacts the face and...

News Image
2 years ago - Seeking Alpha

Teva settles price-fixing claims with State of Kentucky for $1.41M (NYSE:TEVA)

Teva Pharmaceutical Industries (TEVA) has agreed to pay $1.41M to settle the State of Kentucky's price-fixing claims against the company. Read more here.

Mentions: TEVA WBA CVS ABBV

News Image
2 years ago - Seeking Alpha

Teva settles price-fixing claims with State of Kentucky for $1.41B (TEVA)

Teva Pharmaceutical Industries (TEVA) has agreed to pay $1.41B to settle the State of Kentucky's price-fixing claims against the company. Read more here.

Mentions: TEVA WBA CVS ABBV

News Image
2 years ago - Seeking Alpha

Walgreens to pay $500M to settle opioid litigation in New Mexico (NASDAQ:WBA)

Walgreens (WBA) has agreed to pay $500M to the State of New Mexico to settle litigation stemming from how it handled prescriptions for opioids in that state. Read more here.

Mentions: WBA KR WMT ACI ...

News Image
2 years ago - Seeking Alpha

Teva, Walgreens, CVS, AbbVie to pay $17.3B in national opioid settlement (NYSE:TEVA)

Teva Pharmaceutical Industries (TEVA), Walgreens Boots Alliance (WBA), CVS Health (CVS) and AbbVie's (ABBV) Allergan will pay $17.3B as part of a national opioid settlement.

Mentions: WBA TEVA CVS ABBV

News Image
2 years ago - Yahoo Finance

UPDATE 1-AstraZeneca to stop developing Crohn's disease drug

British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.

News Image
2 years ago - Seeking Alpha

Pfizer bond offering to fund Seagen deal among largest

Pfizer (PFE) got over $85B orders Tuesday in an investment-grade jumbo bond sale, one of the biggest in history, to fund its Seagen (SGEN) acquisition. Read more here.

Mentions: PFE SGEN ABBV T

News Image
2 years ago - Seeking Alpha

Cutera new advisor Taylor Harris said to be likely CEO candidate (NASDAQ:CUTR)

Taylor Harris, who was appointed to the Cutera (CUTR) board earlier this week amid a cooperation agreement with two large shareholders, is said to be a likely candidate for the...

Mentions: CUTR

News Image
2 years ago - Barron's

Meet the 100 Women Who Are Leading Finance Into the Future

Our fourth annual list highlights leaders who have taken diverse paths to positions of prominence. Here’s how they’re influencing change in corporate boardrooms, the government, the Fed, and more.

Mentions: USB

News Image
2 years ago - Seeking Alpha

Endo launches 1st generic of Allergan's ulcer bacterial infection drug Pylera

Endo International (ENDPQ) said its operating company Par Pharmaceutical started shipping the first generic version of Allergan's Pylera 140 mg, 125 mg and 125 mg capsules in the...

News Image
2 years ago - Seeking Alpha

Beauty Health stock falls amid new short report from The Bear Cave

Beauty Health Co. (SKIN) dropped 7% amid a new short report from The Bear Cave.The Bear Cave report highlights competition that Beauty Health's HydraFacial device has with DiamondGlow,...

Mentions: SKIN ABBV

News Image
2 years ago - CNBC

Top 10 things the Club is watching in the stock market Wednesday: Retail sales up, stocks dip, Airbnb soars

The Dow, the S&P 500 and the Nasdaq are set to open lower as investors digest the implications of Wednesday's stronger retail sales.

Mentions: BAC JPM KHC

News Image
2 years ago - Reuters

Bausch + Lomb to name Brent Saunders as CEO - WSJ

Eye-care company Bausch + Lomb Corp is expected to name Brent Saunders, the former chief executive of Allergan, as its CEO and chairman of board, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.